Imovane 7.5 mg provides symptomatic relief from sleeplessness characterized by difficulty in falling asleep and frequent nocturnal awakenings and/or early morning awakenings. It should be used for short-term treatment, usually 7-10 days, not more than 3 weeks at a time (see WARNINGS).
Patients with Chronic Insomnia
Use of IMOVANE should be discontinued in patients with chronic insomnia who have been taking zopiclone continuously for at least 4 months. This is because a reduction in sleep efficiency may occur. The patient should be re-evaluated if symptoms of insomnia persist.
Benzodiazepines, Other CNS Depressants:
The risk of respiratory depression and sedation is increased when IMOVANE is taken concomitantly with other sedatives, especially opioids. In patients already receiving an opioid analgesic, prescribe a lower initial dose of IMOVANE and titrate based on clinical response.
Elderly patients are especially susceptible to drowsiness and other adverse effects related to zopiclone. Dosage should be lowered when IMOVANE is prescribed in elderly patients.
Complex sleep-related behaviors such as “sleep-driving” have been reported in some patients who took IMOVANE at therapeutic doses and did not remember doing activities such as leaving the house, making and eating food, talking on the phone, or driving a car while not fully awake.
These behaviors can be dangerous and should not be tolerated by the patient or people around them.
Overdose with buy zopiclone onlinecan be fatal in some patients. The patient must receive only the lowest possible dose to reduce the risk of intentional overdose. It is also very important to immediately contact a physician and report all overdoses.
Besides a drowsy appearance, other principal effects of overdose include nausea, vomiting, dizziness, and lethargy.